Asked by: Mary Glindon (Labour - North Tyneside)
Question to the Department for Work and Pensions:
To ask the Secretary of State for Work and Pensions, if he will make an assessment of the potential impact of proposed changes to Work Capability Assessments on people with Parkinson's disease.
Answered by Mims Davies - Minister of State (Department for Work and Pensions)
The Work Capability Assessment (WCA) assesses individuals against a set of descriptors to determine how their health condition or disability affects their ability to work. The WCA takes into account the functional effects of fluctuating and degenerative conditions such as Parkinson’s. A key principle is that the WCA considers the impact that a person’s disability or health condition has on them, not the condition itself.
Claimants with the most severe health conditions and disabilities whose condition is unlikely to ever improve are no longer routinely reassessed.
From 2025, we are reforming the WCA to reflect new flexibilities in the labour market and greater employment opportunities for disabled people and people with health conditions, whilst maintaining protections for those with the most significant conditions. Claimants who currently have no work-related requirements, except in some very limited circumstances, will not be reassessed or lose benefit because of these changes.
When making decisions on changes to the WCA, we carefully considered over 1300 consultation responses, including from disabled people, people with health conditions, and the organisations that represent and support them. We also engaged directly with clinical experts, employer groups and disability organisations across the country.
With these changes to the WCA criteria, 371,000 fewer people will be assessed as having limited capability for work and work-related activity by 2028-29 and will receive personalised support to help them move closer to employment. A further 29,000 individuals will be found fit for work by 2028-29 and will receive more intensive support to search for and secure work than would be the case under the current WCA rules. These figures are not based on specific conditions. This is because the WCA considers the impact that a person’s disability or health condition has on their ability to work, not the condition itself.
The department routinely engages with a wide range of organisations that represent and support disabled people and people with health conditions, including people living with Parkinson’s disease.
Asked by: Peter Dowd (Labour - Bootle)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether the NHS Long Term Workforce Plan will include steps to help tackle regional variations in access to Parkinson’s specialist care.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The NHS Long Term Workforce Plan (LTWP) sets out the steps the National Health Service and its partners need to take to deliver an NHS workforce that meets the changing needs of the population over the next 15 years. It covers the majority of NHS workforce groups, including those working on Parkinson’s disease. The LTWP commits to working closely with systems to consider the best approaches to reviewing the geographical distribution of training posts for wider professional groups.
Asked by: Mary Glindon (Labour - North Tyneside)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if she will amend the NHS long-term workforce plan to help tackle regional variations in access to Parkinson’s specialist care.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The NHS Long Term Workforce Plan (LTWP) sets out the steps the National Health Service and its partners need to take to deliver an NHS workforce that meets the changing needs of the population over the next 15 years. It covers the majority of NHS workforce groups, including those working on Parkinson’s disease. The LTWP commits to working closely with systems to consider the best approaches to reviewing the geographical distribution of training posts for wider professional groups.
Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether she has made an assessment of the potential merits of issuing warm home prescriptions to patients with Parkinson's disease.
Answered by Helen Whately - Minister of State (Department of Health and Social Care)
We have made no specific assessment. The Government recognises that warm home prescription schemes can be effective in helping to protect vulnerable people and households from the health impacts of living in a cold home. These schemes are good examples of local collaboration between the National Health Service, local government, and other partners.
Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps she is taking to help ensure patients diagnosed with Parkinson's disease receive an appointment with a specialist within six weeks.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The National Institute for Health and Care Excellence’s (NICE) guidance, Parkinson’s disease: Diagnosis and management in primary and secondary care, updated in 2017, sets out best practice for clinicians in the identification and treatment of Parkinson’s disease in line with the latest available evidence. The guidance states that if Parkinson’s disease is suspected, people should be referred quickly and without treatment to a specialist with expertise in the differential diagnosis of this condition.
We expect integrated care boards (ICBs) and National Health Service trusts to have due regard to relevant NICE guidelines. It is the responsibility of ICBs to make available the appropriate provision to meet the health and care needs of their local population, in line with these NICE guidelines.
More generally, cutting waiting lists is one of the Prime Minister’s top priorities. We are making good progress on tackling the longest waits, to ensure patients get the care they need when they need it. Ambitions to eliminate long waits were set out in the elective recovery plan, with the overall aim of eliminating waits of over a year for elective care, by March 2025.
To facilitate this across elective services, we are increasing activity, with plans to spend more than £8 billion from 2022/23 to 2024/25. This includes expanding capacity through the creation of a new network of community diagnostic centres, and maximising all available independent sector capacity.
Asked by: Paul Girvan (Democratic Unionist Party - South Antrim)
Question to the Department for Work and Pensions:
To ask the Secretary of State for Work and Pensions, what steps he is taking to support people with (a) Parkinson's and (b) other long-term conditions with their basic financial outgoings.
Answered by Mims Davies - Minister of State (Department for Work and Pensions)
People on low, or no income or earnings who have a health condition or disability which restricts the amount of work they can do, can claim Universal Credit (UC). They must provide medical evidence to support their claim - most commonly a Statement of Fitness for Work, usually referred to as a fit note. Claimants whose health condition or disability continues for four weeks or more are referred for a work capability assessment (WCA). The WCA determines how an individual’s health condition or disability affects their ability to work. A key principle is that the WCA considers the impact a person’s disability or health condition has on them, not the condition itself.
Where it has been decided that claimants have limited capability for work (LCW) or limited capability for work and work-related activity (LCWRA), they will be entitled to a work allowance, and in couple claims where one is working, access to help with childcare costs. Where it has been decided that claimants have LCWRA, they may be entitled to the award of an additional amount of benefit – the LCWRA addition – which is £390.06 per month (2023-24 rates).
Where it has been decided that claimants have LCW, they are not reasonably expected to look for work at present but are expected to prepare for work in the future. Where it has been decided that claimants have LCWRA, they are not expected to look for work or required to undertake any work-related activity. Where it has been decided that claimants are fit for work, they are expected to undertake work-related activity and to look for work.
People whose capability for work is impacted because they are disabled or have a health condition, including people who have Parkinson’s and other long term health conditions, may also be eligible for New Style Employment and Support Allowance (NS ESA) subject to satisfying both the basic and National Insurance contribution conditions. NS ESA is an earnings replacement benefit for working age people who are unable to work due to a health condition or disability. In addition to the support provided for basic financial outgoings by UC people with a long-term health condition or disability may be entitled to support with disability-related extra costs through benefits such as Personal Independence Payment.
Asked by: Taiwo Owatemi (Labour - Coventry North West)
Question to the HM Treasury:
To ask the Chancellor of the Exchequer, what assessment he has made of the implications for his policies of the recommendations in the report entitled Still nowhere near enough, published by Parkinson’s UK on 26 February 2024.
Answered by Laura Trott - Chief Secretary to the Treasury
HM Treasury ministers have regular discussions with Department for Health and Social Care ministers on a range of issues, including meetings between the Chancellor and the Secretary of State
The Government delivers a wide range of support to help those with disabilities and long-term health conditions, such as Parkinson’s. If individuals incur extra costs whilst performing tasks associated with daily living, then they may qualify for disability benefits such as Personal Independence Payment (PIP) and Attendance Allowance (AA). This extra support can be worth over £8,900 per year and is due to increase from April by 6.7%. Depending on their needs, additional support for those with Parkinson’s may be available via local authorities who deliver adult social care services.
Asked by: Taiwo Owatemi (Labour - Coventry North West)
Question to the HM Treasury:
To ask the Chancellor of the Exchequer, what steps he is taking to support people with (a) Parkinson's and (b) other long-term conditions to cover everyday expenses.
Answered by Laura Trott - Chief Secretary to the Treasury
HM Treasury ministers have regular discussions with Department for Health and Social Care ministers on a range of issues, including meetings between the Chancellor and the Secretary of State
The Government delivers a wide range of support to help those with disabilities and long-term health conditions, such as Parkinson’s. If individuals incur extra costs whilst performing tasks associated with daily living, then they may qualify for disability benefits such as Personal Independence Payment (PIP) and Attendance Allowance (AA). This extra support can be worth over £8,900 per year and is due to increase from April by 6.7%. Depending on their needs, additional support for those with Parkinson’s may be available via local authorities who deliver adult social care services.
Asked by: John Hayes (Conservative - South Holland and The Deepings)
Question to the HM Treasury:
To ask the Chancellor of the Exchequer, what steps he is taking to support people with (a) Parkinson's and (b) other long-term conditions to cover everyday expenses.
Answered by Laura Trott - Chief Secretary to the Treasury
HM Treasury ministers have regular discussions with Department for Health and Social Care ministers on a range of issues, including meetings between the Chancellor and the Secretary of State
The Government delivers a wide range of support to help those with disabilities and long-term health conditions, such as Parkinson’s. If individuals incur extra costs whilst performing tasks associated with daily living, then they may qualify for disability benefits such as Personal Independence Payment (PIP) and Attendance Allowance (AA). This extra support can be worth over £8,900 per year and is due to increase from April by 6.7%. Depending on their needs, additional support for those with Parkinson’s may be available via local authorities who deliver adult social care services.
Asked by: Tonia Antoniazzi (Labour - Gower)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions she has had with the Medicines and Healthcare products Regulatory Agency on the average licensing approval decision timelines for (a) generic and (b) biosimilar medicines to treat Parkinson's disease.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Medicines and Healthcare products Regulatory Agency (MHRA) is taking urgent action to deliver improvements to decision timescales in established medicines, including those indicated to treat Parkinson’s disease. Last week we approved additional licences for this critical area. Whilst no specific discussions have taken place between the MHRA and my Rt hon. Friend, the Secretary of State for Health and Social Care on this matter, we are taking significant steps to assess applications for medicine approval within statutory timeframes and will always prioritise applications according to public health need.
We are working to reduce timelines by bringing in additional resources and developing processes that will result in significantly improved response times, while protecting patient safety. The measures we are putting in place are already resulting in significant improvements, and we will continue to publish monthly updates providing applicants with transparent information on expected timescales. As an effective regulator, we are committed to the highest of standards of performance and delivering the right outcomes for patients and public health.